Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio20.80
Quick Ratio20.80
Price-To-Earnings
Trailing P/E Ratio-19.50
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 million
Price / Sales567.77
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book5.40
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-3,300.12%
Return on Equity-26.20%
Return on Assets-24.58%
Miscellaneous
Employees18
Outstanding Shares173,080,000
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) posted its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company had revenue of $0.32 million for the quarter. Geron had a negative net margin of 3,300.12% and a negative return on equity of 26.20%. During the same period last year, the firm posted ($0.05) EPS. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
4 equities research analysts have issued 12 month price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Geron's share price to reach $5.50 in the next twelve months. View Analyst Ratings for Geron.
Are investors shorting Geron?
Geron saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 42,678,450 shares, an increase of 2.6% from the May 15th total of 41,615,441 shares. Based on an average daily volume of 5,817,424 shares, the days-to-cover ratio is presently 7.3 days. Approximately 24.8% of the company's stock are short sold. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include TESARO (TSRO), Clovis Oncology (CLVS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Global Blood Therapeutics (GBT), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP) and Puma Biotechnology (PBYI).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
- Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
- Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
- Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)
Has Geron been receiving favorable news coverage?
News articles about GERN stock have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Geron earned a daily sentiment score of 0.07 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.18 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Geron's major shareholders?
Geron's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.37%), Northern Trust Corp (1.12%), Swiss National Bank (0.18%), Arnhold LLC (0.10%), A.R.T. Advisors LLC (0.09%) and NJ State Employees Deferred Compensation Plan (0.09%). View Institutional Ownership Trends for Geron.
Which institutional investors are selling Geron stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., NJ State Employees Deferred Compensation Plan, Northern Trust Corp, MetLife Investment Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Geron.
Which institutional investors are buying Geron stock?
GERN stock was bought by a variety of institutional investors in the last quarter, including Arnhold LLC, M Holdings Securities Inc., OMERS ADMINISTRATION Corp, UBS Group AG, A.R.T. Advisors LLC, Bayesian Capital Management LP, Element Capital Management LLC and Swiss National Bank. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $3.51.
How big of a company is Geron?
Geron has a market capitalization of $649.05 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
